Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws

Oral Dis. 2018 Mar;24(1-2):52-56. doi: 10.1111/odi.12783.

Abstract

Antiresorptive agent-related osteonecrosis of the jaw is a rare but significant complication in patients using antiresorptive agents such as bisphosphonates and denosumab. Although the disease is well recognized, and many studies have been performed on the management of this condition, the treatment of severe osteonecrosis is still a challenge. Most recent studies have shown an advantage of surgical treatment over conservative treatment for stage 2/3 patients, but there is no consensus on the appropriate surgical procedures for antiresorptive agent-related osteonecrosis of the jaw. Furthermore, patients with severe systemic conditions may not be appropriate for extensive surgical treatment, and the treatment protocol for such patients has not been established. In this review, issues regarding the current surgical treatment for antiresorptive agent-related osteonecrosis of the jaws are discussed, with an emphasis on the clinical aspects.

Keywords: antiresorptives; bisphosphonate; bisphosphonate-related osteonecrosis of the jaws; osteonecrosis; osteonecrosis of the jaws; surgical management.

Publication types

  • Review

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / surgery*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / therapy
  • Bone Density Conservation Agents / adverse effects*
  • Conservative Treatment*
  • Denosumab / adverse effects
  • Diphosphonates / adverse effects
  • Humans
  • Laser Therapy
  • Piezosurgery
  • Severity of Illness Index

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab